Nenad Grmusa active positions
| Companies | Position | Start | End |
|---|---|---|---|
DEM BioPharma, Inc.
 DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Director/Board Member | 2022-09-21 | - |
| Chief Executive Officer | 2022-09-21 | - |
Career history of Nenad Grmusa
Former positions of Nenad Grmusa
| Companies | Position | Start | End |
|---|---|---|---|
| CHORDIA THERAPEUTICS INC. | Director/Board Member | - | - |
Statistics
International
| Japan | 2 |
| United States | 2 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CHORDIA THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Nenad Grmusa
- Experience
